NCT04007276Not yet recruitingPhase 4
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 26 Jun 2019
- Start date
- 1 Nov 2027
- Primary completion date
- 30 Nov 2031
- Lead sponsor
- Tulane University
- Diseases
- Glaucoma
- NCT number
- NCT04007276
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 1 Nov 2027 to the primary completion date, 30 Nov 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No surgery within the past 6 months
- Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study
Other illness
- Known allergy or sensitivities to brimonidine
- No history of lid surgery or botox
- Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator
Other
- Pregnancy
- Prisoners
- Inability to sit comfortably for 30 minutes
Who the study is looking for
- Age \> 18 years
- Diagnosis of primary open angle glaucoma
- Willing and able to give informed consent
- Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tulane University Medical Center Coordinator of this site? Confirm its status | New Orleans | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.